Illumina, Inc. $ILMN Shares Sold by Canada Post Corp Registered Pension Plan

Canada Post Corp Registered Pension Plan trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 36.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,783 shares of the life sciences company’s stock after selling 5,700 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Illumina were worth $1,283,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB lifted its stake in Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after purchasing an additional 79 shares in the last quarter. HighPoint Advisor Group LLC lifted its stake in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares in the last quarter. Assetmark Inc. lifted its stake in Illumina by 10.2% during the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after purchasing an additional 96 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in Illumina by 4.2% during the fourth quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after purchasing an additional 99 shares in the last quarter. Finally, Creative Capital Management Investments LLC lifted its stake in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on ILMN. UBS Group restated a “neutral” rating and set a $135.00 price target on shares of Illumina in a research note on Friday, February 6th. Royal Bank Of Canada began coverage on Illumina in a research note on Thursday. They set an “outperform” rating and a $170.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Stifel Nicolaus increased their price objective on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Guggenheim increased their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $137.75.

Illumina Stock Down 0.7%

Shares of NASDAQ ILMN opened at $141.51 on Tuesday. The stock has a market cap of $21.41 billion, a P/E ratio of 25.73, a PEG ratio of 2.36 and a beta of 1.42. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12-month low of $78.55 and a 12-month high of $155.53. The business’s fifty day simple moving average is $128.84 and its 200-day simple moving average is $130.03.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Insider Activity at Illumina

In related news, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 332,530 shares of company stock valued at $48,303,655 over the last quarter. 2.90% of the stock is owned by insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.